within Pharmacolibrary.Drugs.ATC.C;

model C09XA54
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 0.00013333333333333334,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.135,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006666666666666667,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C09XA54</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>This drug is a fixed-dose combination tablet of aliskiren (a direct renin inhibitor), amlodipine (a calcium channel blocker), and hydrochlorothiazide (a thiazide diuretic), used for the treatment of hypertension (high blood pressure) in adults when blood pressure is not adequately controlled with single or dual therapy. Aliskiren/amlodipine/hydrochlorothiazide combination is an approved antihypertensive therapy.</p><h4>Pharmacokinetics</h4><p>No published population pharmacokinetic studies found for the fixed-dose triple combination; parameters are estimated based on known PK of individual components in healthy adults following oral administration.</p><h4>References</h4><ol><li><p>Gradman, AH, &amp; Traub, D (2007). The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension. <i>Reviews in cardiovascular medicine</i> 8 Suppl 2 S22–S30. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17401313/\">https://pubmed.ncbi.nlm.nih.gov/17401313</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C09XA54;
